close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Molecular Partners AG - American Depositary Shares (NQ:MOLN)

4.480 +0.850 (+23.42%)
Streaming Delayed Price Updated: 10:26 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Molecular Partners AG - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting
From Molecular Partners
Via GlobeNewswire
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025
From Molecular Partners
Via GlobeNewswire
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025
From Molecular Partners
Via GlobeNewswire
Looking Into Molecular Partners's Recent Short Interest
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025
From Molecular Partners
Via GlobeNewswire
Earnings Scheduled For August 25, 2025
 
Via Benzinga
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics
From Molecular Partners
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025
From Molecular Partners
Via GlobeNewswire
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025
From Molecular Partners
Via GlobeNewswire
Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway
From Molecular Partners
Via GlobeNewswire
Molecular Partners to Present at Upcoming Investor Conferences
From Molecular Partners
Via GlobeNewswire
Molecular Partners Reports Financial Results and Highlights from Q1 2025
From Molecular Partners
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025
From Molecular Partners
Via GlobeNewswire
Molecular Partners Announces all Board Proposals Approved at Annual General Meeting
From Molecular Partners
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Molecular Partners to hold three poster presentations at AACR 2025
From Molecular Partners
Via GlobeNewswire
Molecular Partners Publishes Invitation to Annual General Meeting 2025
From Molecular Partners
Via GlobeNewswire
Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024
From Molecular Partners
Via GlobeNewswire
Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call
From Molecular Partners
Via GlobeNewswire
Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer
From Molecular Partners
Via GlobeNewswire
Earnings Scheduled For March 6, 2025
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today